Vaccine最新文献

{"title":"Uptake of HPV vaccination and associated factors in France: a nationwide study from 2007 to 2023","authors":"Lucas Dufour ,&nbsp;Jérôme Drouin ,&nbsp;Rosemary Dray-Spira ,&nbsp;Stéphane Le Vu","doi":"10.1016/j.vaccine.2026.128308","DOIUrl":"10.1016/j.vaccine.2026.128308","url":null,"abstract":"<div><h3>Background</h3><div>Although HPV vaccination coverage has remained low in France, information on barriers to vaccination is incomplete. This nationwide study aimed to assess HPV vaccination uptake and associated factors alongside the evolving recommendations since its implementation.</div></div><div><h3>Methods</h3><div>Using data from the French National Health Data System (SNDS), all individuals aged 10–29 years were included. Annual HPV vaccination uptake between 2007 and 2023 was assessed by age group and sex. Associations between individuals' socio-demographic, healthcare use and access and medical characteristics with HPV vaccination were assessed using multivariable logistic regression models.</div></div><div><h3>Findings</h3><div>Among 27.9 million (M) individuals included, 5.9M received HPV vaccination: 3.4M (2.7M females/0.7M males) aged 10–14, 2.2M (1.9M/0.3M) aged 15–19, and 0.28M (240,000/40,000) aged 20–29. Annual vaccination uptake consistently increased since 2012, reaching up to 17.1% and 15.7% of 10–14-year-old females and males in 2023. Across all age and sex groups, socioeconomic disadvantage was associated with lower odds of vaccination (adjusted odds ratios ranging from 0.45 to 0.84 for complementary health insurance allowance beneficiaries, and from 0.55 to 0.73 for those living in the most deprived quintile of municipalities), and these disparities widened over time among females aged 10–19. While probability of HPV vaccination increased with the number of contacts with the primary healthcare system, Down syndrome, diabetes and mental health disorders were associated with decreased odds of HPV vaccination.</div></div><div><h3>Interpretation</h3><div>Until 2023, disadvantaged young people, those with limited access to healthcare or suffering from chronic illnesses, benefited less from HPV vaccination than those more privileged.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128308"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring rural-urban disparities in HPV vaccine initiation: new insights from the 2022 national health interview survey","authors":"Jason Semprini ,&nbsp;Heather Brandt","doi":"10.1016/j.vaccine.2026.128334","DOIUrl":"10.1016/j.vaccine.2026.128334","url":null,"abstract":"<div><div>As human papillomavirus (HPV)-associated cancers continue rising in rural America, identifying contributors to rural-urban gaps in HPV vaccination could inform public health priorities and targeted interventions. Analyzing nationally representative data from the 2022 National Health Interview Survey (NHIS), we evaluated rural-urban differences in HPV vaccination among individuals aged 9–29 years (all of whom were recommended to receive the HPV vaccine during adolescence since 2006). Generalized structural equation models adjusted for complex survey design, sociodemographic factors, and other vaccine utilization. Even after adjusting for other vaccine utilization, rural participants were 5.4%-points (CI = −9.7, −1.0) less likely to receive the HPV vaccine than urban participants. Rural-urban disparities in HPV vaccination varied by healthcare access barriers and geography, with the largest gap found in participants who were privately insured. Our work suggests that rural-urban disparities in HPV vaccination are driven by factors distinct from those associated with other vaccines and healthcare access.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128334"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel SARS-CoV-2 mRNA virus-like particle vaccine is highly potent and well tolerated in adults in a phase 1 randomized clinical trial","authors":"Temitope Oyedele ,&nbsp;Rachel Park ,&nbsp;Kelly Morales ,&nbsp;Manish Jain ,&nbsp;Lawrence Sher ,&nbsp;Apinya Vutikullird ,&nbsp;Abby Isaacs ,&nbsp;Brett Jepson ,&nbsp;Kathryn Shoemaker ,&nbsp;Ann Marie Stanley ,&nbsp;Joseph Lee ,&nbsp;Cindy Handelsman ,&nbsp;Stacey Cromer Berman ,&nbsp;Lee-Jah Chang","doi":"10.1016/j.vaccine.2026.128304","DOIUrl":"10.1016/j.vaccine.2026.128304","url":null,"abstract":"<div><h3>Background</h3><div>The need for SARS-CoV-2 vaccines with improved potency, lower reactogenicity, broader coverage, and prolonged protection persists. We examined the safety and immunogenicity of two ferritin scaffold-based self-assembling SARS-CoV-2 mRNA virus-like particle (VLP) vaccines.</div></div><div><h3>Methods</h3><div>In this, randomized, Phase I, open-label, active-controlled study (<span><span>www.clinicaltrials.gov</span><svg><path></path></svg></span> <span><span>NCT06147063</span><svg><path></path></svg></span>) participants received a single 5 μg or 10 μg intramuscular injection of AZD9838 (BA.4/5 variant) or AZD6563 (XBB.1.5 variant), or 30 μg BNT162b2, a licensed mRNA vaccine (XBB.1.5 variant).</div><div>The primary safety endpoint was the incidence of solicited adverse reactions (ARs) through Day 8, unsolicited adverse events (AEs) through Day 29, and serious AEs (SAEs), medically attended AEs (MAAEs), and AEs of special interest (AESIs) through Day 361. The primary immunogenicity endpoint was to characterize the neutralizing antibody (nAb) responses to the ancestral and Omicron (BA.4/5, XBB.1.5) variants at Day 29; characterization of nAb response to Omicron JN.1 was an exploratory analysis.</div></div><div><h3>Results</h3><div>In total, 166 participants aged 18–64 years and 76 participants ≥65 years of age were vaccinated. AZD9838 and AZD6563 were well-tolerated at both dosages. Overall, fewer solicited ARs were reported with AZD9838 and AZD6563 versus BNT162b2. Unsolicited AEs were similar between groups; no related SAEs, AESIs, or MAAEs were reported to Day 180.</div><div>Day 29 nAb GMTs were higher following 10 μg AZD6563 versus 5 μg and higher than AZD9838 across variants and age groups, remaining above baseline and similar to BNT162b2 at Day 180; 10 μg AZD6563 resulted in nAb GMTs similar to BNT162b2 in both age groups.</div></div><div><h3>Conclusion</h3><div>By combining mRNA vaccine technology with VLP-based antigen display, we developed two candidate SARS-CoV-2 vaccines, AZD9838 and AZD6563, that were well tolerated versus a licensed mRNA vaccine, BNT162b2. Furthermore, the variant-matched AZD6563 generated a similar immunogenicity to BNT162b2 but at one third of the dosage (10 μg versus 30 μg).</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128304"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146145175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Humoral immunity induced by XEC monovalent vaccines against SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2","authors":"Keiya Uriu ,&nbsp;Yu Kaku ,&nbsp;Yusuke Kosugi ,&nbsp;Luo Chen ,&nbsp;Naoya Itoh ,&nbsp;Yoshifumi Uwamino ,&nbsp;Hiroshi Fujiwara ,&nbsp;Hironori Satoh ,&nbsp;The Genotype to Phenotype Japan (G2P-Japan) Consortium ,&nbsp;Kei Sato","doi":"10.1016/j.vaccine.2026.128311","DOIUrl":"10.1016/j.vaccine.2026.128311","url":null,"abstract":"<div><div>The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron variant has continuously diverged, and multiple of its sublineages are circulating worldwide. To reduce the coronavirus disease 2019 (COVID-19) with infection of the SARS-CoV-2 Omicron sublineages, some types of variant-matched vaccines have been developed and approved, such as Omicron JN.1-based vaccines and Omicron LP.8.1-based vaccines, in multiple countries, including Japan. Since, at the beginning of 2025, the Omicron XEC variant was predominant over other variants in Japan, two Japanese pharmaceutical companies have developed Omicron XEC-based vaccines. In this study, we evaluated the neutralizing antibody response induced by Omicron XEC-based vaccine and our data showed that both Omicron XEC-based vaccines can enhance the neutralizing titer of sera against a broad range of SARS-CoV-2 variants.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128311"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human papillomavirus (HPV) vaccine coverage and associated sociodemographic factors among individuals eligible for publicly funded vaccine in Ontario, Canada from 2007 to 2023: A Canadian immunization research network study","authors":"Ramandip Grewal ,&nbsp;Jenna Alessandrini ,&nbsp;Sarah E. Wilson ,&nbsp;Alejandro Hernandez ,&nbsp;Nicole E. Basta ,&nbsp;Ann N. Burchell ,&nbsp;Shelley L. Deeks ,&nbsp;Gillian H. Lim ,&nbsp;Christine Navarro ,&nbsp;Gina Ogilvie ,&nbsp;Lauren A. Paul ,&nbsp;Sarah A. Buchan","doi":"10.1016/j.vaccine.2026.128303","DOIUrl":"10.1016/j.vaccine.2026.128303","url":null,"abstract":"<div><div><em>Background</em>: Publicly funded human papillomavirus (HPV) vaccination programs are available for school-aged children to help prevent HPV-associated cancers and other outcomes, with goals of reaching 90% coverage (≥2 doses) in Canada. Since the introduction of gender-neutral programs in Ontario (2016/2017), publicly available coverage estimates by sex and other sociodemographics, particularly throughout the COVID-19 pandemic, have been limited.</div><div><em>Methods</em>: We conducted a population-based cohort study consisting of males and females eligible for publicly funded HPV vaccine programs in Ontario (2007-2023). Using linked vaccination and administrative databases, we estimated vaccine coverage by sex, year, birth cohort, and various sociodemographics. We explored the impacts of the COVID-19 pandemic on coverage by comparing those who first became eligible during pandemic years to those who first became eligible before the pandemic. Multinomial logistic regression was used to report on associations between sociodemographics and vaccination status (unvaccinated, partial vaccination, up-to-date [≥2 doses] vaccination).</div><div><em>Results</em>: Up-to-date coverage varied by birth cohort and sex, ranging from 40-70% among females and 40-66% among males; uptake of at least 1 dose was higher (females:51-77%; males:60-74%). The lowest coverage estimates were among individuals who first became program eligible during the pandemic with some improvement in coverage through catch-up opportunities in later years (i.e., from 3-6% [2019-2021] to 40-51% [2022-2023]). Vaccine coverage, particularly up-to-date vaccination, was associated with socioeconomic status, with individuals in the lowest income neighbourhoods experiencing lower uptake, for example. This trend was most apparent among cohorts who became eligible during pandemic years.</div><div><em>Conclusions</em>: Following inception of gender-neutral publicly funded programs in Ontario, HPV vaccine coverage for females and males has been substantially short of national goals. Findings suggest a need to improve uptake and access to publicly funded catch-up opportunities. Efforts to reduce inequities in vaccine uptake are crucial to reach targets and close the gap in HPV-associated disparities.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128303"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural determinants of vaccine access: an integrated review of the Canadian literature","authors":"Muhammad Haaris Tiwana ,&nbsp;Julia Smith","doi":"10.1016/j.vaccine.2026.128324","DOIUrl":"10.1016/j.vaccine.2026.128324","url":null,"abstract":"<div><h3>Background</h3><div>Vaccination is a critical public health tool, yet vaccine uptake in Canada is declining, with persistent inequities among marginalized populations. While individual-level vaccine hesitancy is well studied, there is limited synthesis of how structural determinants such as governance, institutional practices, and cultural norms shape access.</div></div><div><h3>Objective</h3><div>To examine how structural determinants shape vaccine access among marginalized populations in Canada.</div></div><div><h3>Methods</h3><div>We conducted an integrative review following the Joanna Briggs Institute (JBI) methodology and reported according to PRISMA-ScR guidelines. Studies were included if they addressed vaccine access in the Canadian context and examined systemic inequities affecting marginalized populations. Data from 40 sources were charted and analyzed thematically using a structural determinant of health framework, which categorized findings into four domains: (1) values, beliefs, culture, and norms; (2) governance; (3) laws, policies, regulations, and budgets; and (4) institutional practices.</div></div><div><h3>Results</h3><div>Structural determinants affected vaccine access in multiple, intersecting ways. Cultural mistrust, religious concerns, and social norms influenced perceptions of vaccine safety and relevance. Governance issues including top-down strategies, lack of community engagement, and inconsistent communication undermined public trust. Legal and policy barriers, such as identification requirements, excluded marginalized populations. Institutional practices, including inaccessible clinic locations, and absence of race-based data, further contributed to inequities. Positive examples of community- and peer-led interventions were identified but often underfunded or excluded from formal systems.</div></div><div><h3>Conclusions</h3><div>Addressing these barriers requires participatory governance, culturally safe services, and sustained investment in community-led models. Our framework can inform equity-focused vaccine policy and practice in Canada and similar high-income contexts.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128324"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunoinformatics design and in vivo evaluation of a multiepitope vaccine targeting OMPL1, Lipl32, Lipl41, and Lipl46 for leptospirosis in a male ICR mouse model","authors":"Ritik Thumar ,&nbsp;Satyamitra L. Shekh ,&nbsp;Anitaba Chauhan ,&nbsp;Kopal Kapoor ,&nbsp;Aneri Joshi ,&nbsp;Devanshi Gajjar ,&nbsp;Sriram Seshadri ,&nbsp;Dhwani Jhala ,&nbsp;Chaitanya G. Joshi ,&nbsp;Amrutlal Patel","doi":"10.1016/j.vaccine.2026.128331","DOIUrl":"10.1016/j.vaccine.2026.128331","url":null,"abstract":"<div><div>Leptospirosis is the most widespread and under-recognized zoonotic disease with around 1.03 million cases and ∼ 60,000 reported fatalities occurring each year. It is a threat to humans as well as animals and can only be avoided by appropriate immunization. In this study, epitopes from proteins present on the exterior membrane of selected pathogenic <em>Leptospira</em> species were used as immunogens <em>viz.</em> OMPL1, LipL32, LipL41 and LipL46. Conserved epitopes from each of the proteins across 8 species of <em>Leptospira</em> were screened and used to generate a multi-epitope vaccine that activates B cells, CD4+ and CD8+ cells. Six vaccine constructs were analyzed employing various immunoinformatics tools for physicochemical properties, structure prediction followed by validation, docking with immune receptors and molecular dynamics simulation. The vaccine construct 4 (LH) was found to comply with all the desired parameters to further consider for <em>in vivo</em> efficacy evaluation. For <em>in vivo</em> validation, gene for LH was cloned in a pVAX1 vector to be used as a DNA vaccine and in pET30a vector to express protein vaccine. DNA and protein vaccines were administered intramuscularly in ICR male mice along with adjuvant alhydrogel. Both types of vaccines elicited strong immune response evidenced from significantly increased serum IgG level evaluated by ELISA post the duration of 14 to 42 days. IFN-γ cytokine producing T cells were significantly stimulated in protein vaccine as revealed by flow cytometry suggesting the priming of CD4+ and CD8+ T cells by vaccine. The neutralizing antibody response to <em>Leptospira</em> serovars was confirmed with microscopic agglutination test. In summary, this study illustrates the prospective of multi-epitope DNA and protein vaccines incorporating epitopes from four outer membrane proteins to generate a strong immune response, paving the way forward for protection during challenge study against virulent <em>Leptospira</em> pathogens in animal model.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128331"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Willingness to vaccinate in a future pandemic. Evidence from a vignette experiment","authors":"Ádám Stefkovics ,&nbsp;Anna Sára Ligeti ,&nbsp;Júlia Koltai","doi":"10.1016/j.vaccine.2026.128284","DOIUrl":"10.1016/j.vaccine.2026.128284","url":null,"abstract":"<div><div>The COVID-19 pandemic highlighted both the importance of vaccination and the persistent challenge of vaccine hesitancy. As future global outbreaks remain a realistic threat, understanding the factors shaping vaccination intentions beyond the COVID-19 context is crucial. We conducted a pre-registered vignette experiment in an online survey in Hungary (<span><math><mrow><mi>N</mi><mo>=</mo><mn>1000</mn></mrow></math></span>), varying six disease and vaccine-related attributes: disease severity, vaccine’s country of origin, technology, regulatory approval, side effects, and recommendation source. Respondents evaluated eight randomly assigned scenarios each. Multilevel linear models were used to estimate the main and interaction effects of vignette and individual characteristics. Vaccine side effects, approval status, and country of origin were the strongest predictors of willingness to vaccinate in a future pandemic. Respondents were substantially less willing to accept vaccines with stronger side effects or those originating from China, and preferred vaccines jointly approved by Hungarian and European authorities. In contrast, vaccine technology (mRNA vs. non-mRNA) and recommendation source had no significant effect. Less-educated, rural respondents and those unvaccinated against COVID-19 were largely unaffected by differences in vaccine attributes or contextual factors. Concerns over side effects and institutional legitimacy remain central in hypothetical future pandemics, while technological distinctions play a minor role. Strengthening trust through transparent, evidence-based communication, early engagement, and tailored messages addressing the specific concerns of hesitant subgroups not even influenced by disease and vaccine-related factors will be essential to improve vaccine uptake and pandemic preparedness.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128284"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146168642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding parental HPV vaccination decision in China through the lens of vaccine hesitancy and preference heterogeneity: a discrete choice experiment","authors":"Yunshu Lu ,&nbsp;Chengzhou Tang ,&nbsp;Sen Xu ,&nbsp;Iltaf Hussain ,&nbsp;Wei Zhao ,&nbsp;Yi Dong ,&nbsp;Jiaxu Lin ,&nbsp;Runfang Mu ,&nbsp;Xu Ren ,&nbsp;Da Feng ,&nbsp;Shunping Li ,&nbsp;Yu Fang ,&nbsp;Jie Chang","doi":"10.1016/j.vaccine.2026.128307","DOIUrl":"10.1016/j.vaccine.2026.128307","url":null,"abstract":"<div><h3>Background</h3><div>Human papillomavirus (HPV) vaccination is an effective strategy for preventing cervical cancer. However, persistent vaccine hesitancy remains a major barrier to widespread HPV vaccination. In line with the WHO's global strategy to eliminate cervical cancer, China announced in September 2025 that HPV vaccination would be included in the National Immunisation Programme. Understanding how parental preferences for different HPV vaccine attributes differ according to level of vaccine hesitancy is therefore essential to inform effective communication strategies and support the successful implementation of the new national programme.</div></div><div><h3>Methods</h3><div>We recruited parents of girls aged 9–14 years in mainland China who had not received the HPV vaccine. A total of 1062 participants completed a discrete choice experiment to examine parental preferences for vaccinating their children. Five vaccine attributes were evaluated: protection efficacy, duration of protection, possibility of minor side effects, vaccine's country of manufacture, and price. The HPV Vaccine Hesitancy Scale was used to measure participants' degree of vaccine hesitancy. A mixed logit model was employed to explore preference heterogeneity according to level of vaccine hesitancy among participants.</div></div><div><h3>Results</h3><div>All vaccine attributes significantly influenced parental preferences. Protective efficacy and duration of protection were the most important attributes for both high-hesitancy and low-hesitancy parents. Preferences differed by hesitancy level: parents with higher hesitancy assigned greater weight to efficacy and duration, and showed greater preference for imported vaccines. Under the baseline scenario, the predicted uptake was 35.9%, whereas the optimal scenario, characterised by high efficacy, forever protection, low cost, minimal side effects, and domestic production, was projected to increase uptake to 99.2%.</div></div><div><h3>Conclusion</h3><div>Parental preference of HPV vaccine attributes varied across vaccine hesitancy groups. Optimisation of vaccine attributes, particularly protection efficacy and duration of protection, may substantially enhance acceptance, supported by effective public communication and strengthened trust in domestically produced vaccines. These findings provide evidence to inform targeted strategies for increasing HPV vaccination coverage in China.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128307"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146159819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herpes zoster vaccination coverage and associated factors among individuals aged ≥50 years in Zhejiang, China: A population-based cross-sectional study","authors":"Xiaotong Yan,&nbsp;Xiujing Hu,&nbsp;Yue Xu,&nbsp;Xuehai Zhang,&nbsp;Yusui Zhao,&nbsp;Jinhang Xu","doi":"10.1016/j.vaccine.2026.128301","DOIUrl":"10.1016/j.vaccine.2026.128301","url":null,"abstract":"<div><h3>Background</h3><div>The herpes zoster (HZ) vaccination coverage remains low and existing research is limited. This study aimed to investigate factors associated with vaccination coverage and reasons for vaccination/non-vaccination across economic levels among individuals aged ≥50 in Zhejiang province.</div></div><div><h3>Methods</h3><div>A cross-sectional survey was conducted from March to May 2024 using multistage convenience sampling method. 10,500 individuals were recruited from 175 community health centers or township hospitals across 35 counties in Zhejiang Province. Chi-square test and multivariate logistic regression were used to analyze factors associated with vaccination coverage.</div></div><div><h3>Results</h3><div>Among 10,500 participants (mean age: 65.08), the vaccination coverage was 1.93%. Higher education level (college or higher vs primary school or below: OR = 2.609, 95% CI: 1.703–3.996) and doctor's recommendation (OR = 7.311, 95% CI: 5.032–10.621) were key factors associated with higher vaccination coverage. Among participants, vaccination motivations varied by monthly income: family recommendation and community promotion were the main drivers for those with incomes &lt;5000 yuan, whereas “Someone close has had HZ” was most common for those with incomes ≥5000 yuan. The main non-vaccination reason for adults with monthly income of ≤10,000 yuan was “lack of vaccine knowledge”, while “Unnecessary to get vaccinated” was the primary reason for the &gt;10,000 yuan group. Television (64.64%), doctor (59.81%), and family member (50.92%) were the main ways of obtaining vaccine information, and individuals aged ≥70 years preferred to obtain vaccine information from family members compared to those aged 50–59 and 60–69 years.</div></div><div><h3>Conclusion</h3><div>HZ vaccination coverage among individuals aged ≥50 in Zhejiang Province remains low, with higher education and doctor's recommendation identified as key facilitators. A multifaceted strategy is recommended to improve coverage, including targeted health education via trusted channels like television, integrating vaccine prescriptions into clinical practice, and government-subsidized programs to ensure equitable access and reduce disease burden.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"76 ","pages":"Article 128301"},"PeriodicalIF":4.5,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146138191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}